2022
Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness
Wisk L, Gottlieb M, Spatz E, Yu H, Wang R, Slovis B, Saydah S, Plumb I, O’Laughlin K, Montoy J, McDonald S, Lin Z, Lin J, Koo K, Idris A, Huebinger R, Hill M, Gentile N, Chang A, Anderson J, Hota B, Venkatesh A, Weinstein R, Elmore J, Nichol G, Santangelo M, Ulrich A, Li S, Kinsman J, Krumholz H, Dorney J, Stephens K, Black K, Morse D, Morse S, Fernandes A, Sharma A, Stober T, Geyer R, Lyon V, Adams K, Willis M, Ruiz L, Park J, Malone K, Shughart H, Schaeffer K, Shughart L, Arab A, Grau D, Patel A, Watts P, Kelly M, Hunt A, Hannikainen P, Chalfin M, Cheng D, Miao J, Shutty C, Chavez S, Kane A, Marella P, Gallegos G, Martin K, L'Hommedieu M, Chandler C, Diaz Roldan K, Villegas N, Moreno R, Eguchi M, Rodriguez R, Kemball R, Chan V, Chavez C, Wong A, Hall A, Briggs-Hagen M. Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness. JAMA Network Open 2022, 5: e2244486. PMID: 36454572, PMCID: PMC9716377, DOI: 10.1001/jamanetworkopen.2022.44486.Peer-Reviewed Original ResearchConceptsCOVID-19 positive groupCOVID-19-negative groupSARS-CoV-2 infectionCOVID-19 testCOVID-19 resultsSymptomatic illnessSymptomatic SARS-CoV-2 infectionNegative COVID-19 resultsSARS-CoV-2 statusSARS-CoV-2 test positivityPositive COVID-19 testSARS-CoV-2 testNegative COVID-19 testLongitudinal registry studyOutcomes Measurement Information SystemPatient-reported outcomesHealth care usePositive COVID-19 resultMultivariable regression analysisMeasurement Information SystemCOVID-19 testingNegative test resultsCohort studyRegistry studyPROMIS scores
2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviors